Arcus Biosciences Inc (RCUS)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | -4.27% | -0.02% | 4.59% | 4.61% | 4.52% | 76.42% | 77.45% | 79.17% | 81.33% | 6.57% | 58.82% | 57.79% | 60.71% | 60.84% | -85.60% | -54.13% | -41.27% | -211.08% | -73.31% | -46.27% |
| Operating profit margin | -290.60% | -270.62% | -258.17% | -251.27% | -250.00% | 17.32% | 16.36% | 14.97% | 13.56% | -523.15% | -183.75% | -181.14% | -159.96% | -115.39% | -763.67% | -655.57% | -591.39% | -1,242.89% | -786.51% | -681.14% |
| Pretax margin | -257.26% | -241.30% | -234.25% | -232.78% | -237.50% | 19.06% | 17.02% | 15.18% | 13.81% | -522.39% | -183.27% | -180.44% | -158.49% | -112.63% | -745.18% | -631.95% | -564.73% | -1,180.37% | -736.31% | -613.46% |
| Net profit margin | -262.39% | -245.49% | -236.73% | -234.46% | -238.39% | 18.36% | 16.29% | 14.43% | 13.31% | -522.39% | -183.27% | -180.44% | -158.49% | -112.63% | -745.18% | -631.95% | -564.73% | -1,180.37% | -736.31% | -613.46% |
Arcus Biosciences Inc's profitability ratios depict a concerning trend over the quarters analyzed. The gross profit margin has been consistently high at 100.00%, indicating the company's ability to generate revenue after accounting for the cost of goods sold. However, the operating profit margin, pretax margin, and net profit margin have all shown persistent negative values, reflecting the company's significant operating, pre-tax, and net losses.
The operating profit margin has worsened over the quarters, reaching as low as -290.60% in Q4 2023, signaling that the company's operating expenses are surpassing its sales revenue. The pretax and net profit margins also exhibit deteriorating trends, with both plunging into negative territory consistently. The net profit margin dropped to -262.39% in Q4 2023, suggesting that the company is incurring substantial losses after accounting for operating expenses, taxes, and other costs.
Overall, the data highlights significant profitability challenges for Arcus Biosciences Inc, emphasizing the importance of closely examining cost management strategies and revenue generation efforts to reverse the negative trend in profitability ratios.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -31.05% | -27.12% | -25.66% | -23.84% | -20.82% | 5.38% | 4.53% | 3.87% | 3.39% | -33.22% | -22.15% | -18.00% | -16.06% | -11.07% | -23.80% | -55.83% | -43.68% | -39.02% | -30.78% | -23.32% |
| Return on assets (ROA) | -28.04% | -24.60% | -23.52% | -22.25% | -19.85% | 5.71% | 4.51% | 3.73% | 3.33% | -33.17% | -22.10% | -17.93% | -15.91% | -10.80% | -23.22% | -53.82% | -41.71% | -37.06% | -28.82% | -21.01% |
| Return on total capital | -73.59% | -62.12% | -55.30% | -49.83% | -42.62% | 10.73% | 8.95% | 7.50% | 6.41% | -51.38% | -32.93% | -25.32% | -24.70% | -16.49% | -26.72% | -69.92% | -54.09% | -47.77% | -37.41% | -27.22% |
| Return on equity (ROE) | -66.45% | -56.35% | -50.71% | -46.50% | -40.64% | 11.38% | 8.91% | 7.23% | 6.29% | -51.31% | -32.85% | -25.23% | -24.47% | -16.09% | -26.07% | -67.40% | -51.65% | -45.37% | -35.02% | -24.51% |
Arcus Biosciences Inc's profitability ratios have shown a deteriorating trend over the past four quarters. The Operating ROA has been consistently negative, indicating that the company is unable to generate operating profits from its assets. Similarly, the ROA and ROE ratios are also negative, suggesting that the company is not efficiently utilizing its assets and equity to generate profits for its shareholders.
The Return on Total Capital ratio has also been consistently negative, demonstrating that the company is not generating sufficient returns on the total capital employed. Overall, the declining trend in profitability ratios indicates a concerning financial performance for Arcus Biosciences Inc.